STAT+

Pharmalot Ed Silverman

STAT Plus: Supreme Court rules against Amgen in closely watched case over scope of patent claims

Politics Sarah Owermohle and Brittany Trang

STAT Plus: New Biden science agency ARPA-H launches first program, targeting bone regrowth

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Appellate judges appear skeptical of FDA decisions on abortion pill; FTC widens probe into PBMs

Biotech Damian Garde

STAT Plus: In Belgium, a native son returns to resurrect the drugmaker Galapagos — and ‘to get the trust back’

Pharmalot Ed Silverman

STAT Plus: FTC widens probe into pharmacy benefit managers to include group purchasing organizations

Politics Rachel Cohrs

STAT Plus: House panel takes first steps toward reining in hospitals with ‘site-neutral’ changes

Politics John Wilkerson

STAT Plus: Could an upcoming Supreme Court case make the FDA slower?

Business Alexa Gagosz — Boston Globe

STAT Plus: CVS Health to close clinical trial unit two years after launch

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FTC suit over Amgen spotlights ‘bundling’ deals with insurers; FDA staff says Pfizer RSV vaccine is effective

Biotech Matthew Herper

STAT Plus: PTC Therapeutics’s PKU drug succeeds in trial, but bigger hurdles for company are ahead

Biotech Jason Mast

STAT Plus: A new startup looks to turn the workhorse of gene therapy against cancer

Health Tech Mario Aguilar

STAT Plus: Biotech and pharma execs wrestle with the ‘nightmare’ of developing digital biomarkers

Pharmalot Ed Silverman

STAT Plus: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers

Health Tech Casey Ross

STAT Plus: AI leaders issue a plea to Congress: Regulate us, and quickly

Biotech Andrew Joseph

STAT Plus: FTC files lawsuit to block Amgen’s purchase of Horizon Therapeutics

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FTC may sue to block Amgen deal for Horizon; Supreme Court declines Teva appeal on skinny labeling

Health Tech Mohana Ravindranath

STAT Plus: General Catalyst, Andreessen Horowitz bet on large language models for health care 

Biotech Jonathan Wosen

STAT Plus: Boundless Bio tests a cancer drug targeting once-mysterious DNA loops

Health Isabella Cueto and Olivia Goldhill

STAT Plus: Ketamine clinics’ bust serves as warning of business challenge facing psychedelic therapy

Exclusive Lev Facher

STAT Plus: Biden drug czar to summon naloxone makers to White House to discuss pricing

Hospitals Bob Herman

STAT Plus: Envision Healthcare files for bankruptcy

Pharmalot Ed Silverman

STAT Plus: U.S. Supreme Court declines bid by Teva to hear ‘skinny labeling’ case with implications for generic drug access

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year

Hospitals Bob Herman

STAT Plus: Hospital-insurer tussle in Arizona puts care denials front and center

Health Tech Lizzy Lawrence

STAT Plus: Masimo’s CEO on battling Apple for the health wearable market

Biotech Jason Mast and Adam Feuerstein

STAT Plus: FDA advisory panel narrowly recommends approval for Sarepta’s gene therapy for Duchenne

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: U.S. Senate committee passes PBM bills; Pfizer CEO predicts pharma will sue over Medicare price negotiations

Biotech Adam Feuerstein and Jason Mast

STAT Plus: Tracking the FDA advisory panel on Sarepta’s gene therapy for Duchenne muscular dystrophy